title: Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome.
abstract: OBJECTIVE
  To assess the virological outcome of patients with undetectable human immunodeficiency (HI) viremia switched to tenofovir (TDF)-containing nucleosideonly (NUKE-only) treatments and to investigate the factors influencing the physicians' decision for application of a nonestablished therapy.
  
  
  METHODS
  Patients' characteristics and history were taken from the cohort database. To study the decision-making process, questionnaires were sent to all treating physicians.
  
  
  RESULTS
  49 patients were changed to TDF-containing NUKE-only treatment and 46 had a follow-up measurement of HI viremia. Virological failure occurred in 16 (35%) patients. Virological failure was associated with previous mono or dual therapy and with a regimen including didanosine or abacavir. No failure occurred in 15 patients without these predisposing factors. The main reasons for change to TDF-containing NUKE-only treatment were side effects and presumed favorable toxicity profile. The rationale behind this decision was mainly analogy to the zidovudine/lamivudine/abacavir maintenance therapy.
  
  
  CONCLUSIONS
  TDF-containing NUKE-only treatment is associated with high early failure rates in patients with previous nucleoside reverse transcriptase inhibitor mono or dual therapy and in drug combinations containing didanosine or abacavir but not in patients without these predisposing factors. In HIV medicine, treatment strategies that are not evidence-based are followed by a minority of experienced physicians and are driven by patients' needs, mainly to minimize treatment side effects.
authors.affiliation: Klinik und Poliklinik für Infektiologie, University Hospital of Berne, Switzerland.
authors.forename: Manuela
authors.initials: M
authors.lastname: Buehlmann
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Chave
authors.forename: Markus
authors.initials: M
authors.lastname: Flepp
authors.forename: Veronique
authors.initials: V
authors.lastname: Schiffer
authors.forename: Olivia
authors.initials: O
authors.lastname: Keiser
authors.forename: Hansjakob
authors.initials: H
authors.lastname: Furrer
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D018579:Patient Selection; D010820:Physicians; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D000068698:Tenofovir; D017211:Treatment Failure; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine